Compare · CLPT vs DXCM
CLPT vs DXCM
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $22.98B, about 68.5x CLPT ($335.2M).
- Over the past year, CLPT is down 19.5% and DXCM is down 12.6% - DXCM leads by 6.9 points.
- DXCM has been more active in the news (8 items in the past 4 weeks vs 5 for CLPT).
- DXCM has more recent analyst coverage (25 ratings vs 4 for CLPT).
- Company
- ClearPoint Neuro Inc.
- DexCom Inc.
- Price
- $11.20+0.13%
- $61.44+3.21%
- Market cap
- $335.2M
- $22.98B
- 1M return
- +22.48%
- -1.56%
- 1Y return
- -19.46%
- -12.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 5
- 8
- Recent ratings
- 4
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CLPT
- ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
- SEC Form DEFA14A filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form DEF 14A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Fletcher R John
- SEC Form 4 filed by Girin Pascal E R
- SEC Form 4 filed by Richards Timothy T.
- Amendment: SEC Form SCHEDULE 13G/A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Burnett Joseph
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.